Omkar Speciality Chemicals Limited has released its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the financial statements during a meeting held on August 14, 2026.

The company confirmed that the results, along with the Limited Review Report, have been uploaded to its investor relations page and the websites of the National Stock Exchange of India Limited and BSE Limited. The disclosure was made pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The announcement was signed by Mahendra Kumar Jain, Director/Chairman, on August 15, 2026. No specific financial metrics such as revenue or net profit were included in the provided text.

Regulatory Disclosure

• Quarter Ended: June 30, 2026
• Board Approval Date: August 14, 2026
• Regulation: SEBI LODR Regulations 2015, Reg 30 & 47

Omkar Speciality Chemicals Limited has disclosed delayed standalone financial results for the quarter ended September 30, 2022, through fiscal year 2025, following the National Company Law Tribunal’s (NCLT) approval of its resolution plan on July 31, 2025. The filing, approved by the Board of Directors on August 7, 2026, reveals that the company reported a net loss of ₹190.06 lakh for Q2FY23. The disclosure comes after the company was admitted to the Corporate Insolvency Resolution Process (CIRP) in December 2022, with management transitioning to a new board appointed from January 1, 2026.

The results were reviewed by statutory auditors R.R. Tibrewala & Co., who issued a qualified conclusion citing the company’s negative net worth and ongoing losses. Despite these challenges, the financial statements were prepared on a going concern basis, reflecting the expected revival of operations under the resolution plan submitted by Kshitij Polyline Limited. The filing complies with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

For the quarter ended September 30, 2022, Omkar Speciality Chemicals reported revenue from operations of ₹116.50 lakh, a significant decline from ₹423.10 lakh in the same period last year. Total income stood at ₹117.81 lakh, while total expenses amounted to ₹307.86 lakh. The company incurred a loss before tax of ₹190.06 lakh, which flowed through to the bottom line as no tax expenses were recorded.

The company’s other income for the quarter was ₹1.30 lakh, compared to ₹72.22 lakh in Q2FY22. Employee benefits expense decreased to ₹30.86 lakh from ₹74.52 lakh year-over-year, while finance costs rose to ₹51.23 lakh from ₹148.60 lakh. Depreciation and amortization expenses remained relatively stable at ₹24.56 lakh.

Balance Sheet Position

As of September 30, 2022, the company’s total assets stood at ₹6,897.05 lakh, down from ₹7,217.17 lakh at the end of FY22. Non-current assets included property, plant, and equipment valued at ₹2,548.32 lakh. Current assets comprised trade receivables of ₹151.65 lakh and cash and cash equivalents of ₹10.77 lakh.

On the liabilities side, borrowings increased to ₹22,577.77 lakh from ₹22,551.40 lakh in the previous year. Trade payables remained steady at ₹992.38 lakh. The company’s equity share capital was ₹2,057.80 lakh, but other equity stood at a negative ₹19,375.33 lakh, highlighting the severe erosion of shareholder value during the insolvency period.

What the Numbers Show

The financial data indicates a sharp contraction in operational scale, with revenue dropping by over 70% year-over-year. However, this decline also led to a reduction in absolute losses, with the net loss for Q2FY23 narrowing to ₹190.06 lakh from ₹355.72 lakh in Q2FY22. The decrease in employee benefits and cost of materials consumed suggests a scaled-down operational footprint, likely due to the CIRP proceedings. The stability in borrowings despite negative equity underscores the reliance on debt financing during the resolution process.